The complexity of Alzheimer's disease risk assessment is a critical issue, and a recent study presented at the NSGC 2025 conference has shed light on this topic. Alzheimer's, a devastating disease, affects millions, and understanding its risk factors is crucial for early intervention.
The study, led by Matt Tschirgi, highlights the role of genetic counselors in interpreting complex biomarker results. While the APOE ϵ4/ϵ4 allele is associated with a higher risk of Alzheimer's, the research reveals a surprising finding: many individuals without this allele still exhibit true Alzheimer's disease pathology.
But here's where it gets controversial... Despite the strong association between the APOE ϵ4 allele and Alzheimer's risk, the study found that a significant number of individuals without this allele also showed biomarker evidence of the disease. This challenges the traditional understanding of genetic risk factors and opens up a new avenue for discussion.
The study analyzed data from over 21,000 individuals who underwent beta-amyloid testing. Among them, 27.1% were classified as higher risk, consistent with previous findings. Interestingly, no significant differences were observed between individuals homozygous for APOE ε3 and those with the APOE ε4 allele.
Researchers also looked at p-tau 181 and p-tau 217 testing results. Among those who underwent p-tau 181 testing, almost half showed results consistent with mild cognitive impairment or Alzheimer's-related dementia. Significantly more individuals with the APOE ε4 allele had biomarker results indicating MCI or dementia compared to those without the allele.
However, p-tau 217 testing revealed a different picture. The proportion of individuals with MCI or dementia did not significantly differ between those with the APOE ε3 and ε4 alleles. This discrepancy highlights the need for further research and the expertise of genetic counselors in interpreting such complex results.
And this is the part most people miss... The study authors emphasize the growing importance of genetic counselors as new therapies and biomarker tests emerge. With the availability of APOE testing for many years, the addition of newer blood biomarker assays adds a layer of complexity to counseling discussions regarding dementia and testing.
Certified genetic counselors possess the knowledge to interpret discordant or ambiguous results, supporting informed decision-making for patients. As the field of Alzheimer's research advances, their role becomes increasingly vital.
The study's findings prompt us to reconsider our understanding of genetic risk factors and the role of genetic counselors. It raises questions such as: Are there other genetic factors at play that we haven't yet discovered? How can we improve our counseling strategies to better support individuals at risk of Alzheimer's?
Join the discussion! What are your thoughts on the role of genetic counselors in Alzheimer's risk assessment? Do you think the current understanding of genetic risk factors is sufficient, or is there more to uncover?
